Publications by authors named "P Lewalle"
Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study.
Ann Hematol
November 2024
Article Synopsis
- * A study of 192 patients revealed that MRD-negative patients had significantly better overall survival, disease-free survival, and lower relapse rates compared to MRD-positive patients, with specific MRD testing methods like multiparametric flow cytometry (MFC) and PCR contributing to these findings.
- * The prognosis of MRD-positive patients varied by factors such as age and type of cancer, particularly showing lower disease-free survival in younger AML patients
Article Synopsis
- * Researchers analyzed data from 1,194 CML patients, finding that younger age and absence of comorbidities were linked to higher adherence rates, while older patients faced increased risk of treatment discontinuation.
- * The findings indicate that low adherence contributes to higher mortality and transplantation rates, emphasizing the need for strategies to improve patient adherence in CML treatment.
Immunodeficiency-Centromeric instability-Facial dysmorphism (ICF) syndrome is an inborn error of immunity characterized by progressive immune dysfunction and multi-organ disease usually treated with antimicrobial prophylaxis and immunoglobulin substitution. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment, but data on outcome are scarce. We provide a detailed description of disease characteristics and HSCT outcome in an international cohort of ICF syndrome patients.
View Article and Find Full Text PDFSelecting the most suitable alternative donor becomes challenging in severe aplastic anemia (SAA) when a matched sibling donor (MSD) is unavailable. We compared outcomes in patients with SAA undergoing stem cell transplantation (SCT) from matched unrelated donors (MUD) (n = 1106), mismatched unrelated donors (MMUD) (n = 340), and haploidentical donors (Haplo) (n = 206) registered in the European Society for Blood and Marrow Transplantation database (2012-2021). For Haplo SCT, only those receiving posttransplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis were included.
View Article and Find Full Text PDFMesenchymal stromal/stem cells (MSCs) are considered to be a promising immunotherapeutic tool due to their easy accessibility, culture expansion possibilities, safety profile, and immunomodulatory properties. Although several studies have demonstrated the therapeutic effects of MSCs, their efficacy needs to be improved while also preserving their safety. It has been suggested that cell homeostasis may be particularly sensitive to plant extracts.
View Article and Find Full Text PDF